Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials (Q38013059)

27 August 2017

Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials (English)

1 reference

27 August 2017

0 references

Timothy D Brewerton

1

1 reference

PubMed ID

22628000

27 August 2017

language of work or name

English

0 references

publication date

1 August 2012

1 reference

Current Psychiatry Reports

27 August 2017

1 reference

27 August 2017

14

1 reference

27 August 2017

4

1 reference

27 August 2017

398-405

1 reference

https://scigraph.springernature.com/pub.10.1007/s11920-012-0287-6

27 August 2017

0 references

cites work

Is anorexia nervosa a delusional disorder? An assessment of eating beliefs in anorexia nervosa.

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Comorbidity of eating disorders with bipolar disorder and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Toward a unified theory of serotonin dysregulation in eating and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

New directions in treatment research of anorexia and bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Neurobiology of anorexia and bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18F]MPPF PET scan study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Differences of cortical 5-HT2A receptor binding index with SPECT in subtypes of anorexia nervosa: relationship with personality traits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Serotonin transporter binding after recovery from eating disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Platelet monoamine oxidase activity in underweight and weight-recovered females with anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

The human genetics of anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

The 5-HT2A -1438 A/G and 5-HTTLPR polymorphisms and personality dimensions in adolescent anorexia nervosa: association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Evidence of complex involvement of serotonergic genes with restrictive and binge purge subtypes of anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Association of the 5-HT2c gene with susceptibility and minimum body mass index in anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Altered reward processing in women recovered from anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Epigenetic dysregulation of dopaminergic genes in eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

A meta-analysis of circulating BDNF concentrations in anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Olanzapine therapy in anorexia nervosa: psychobiological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-012-0287-6

Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa.

21 January 2018

1 reference

12 December 2020

Polymorphisms in serotonin-related genes in anorexia nervosa. The first study in Czech population and metaanalyses with previously performed studies.

1 reference

12 December 2020

Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa

1 reference

12 December 2020

Decreased 5-HT2a receptor binding in patients with anorexia nervosa

1 reference

12 December 2020

Medication response in the treatment of patients with anorexia nervosa.

1 reference

12 December 2020

Olanzapine versus placebo for out-patients with anorexia nervosa

1 reference

12 December 2020

Neuroleptics in the short-term treatment of anorexia nervosa. A double- blind placebo-controlled study with sulpiride

1 reference

12 December 2020

Anorexia nervosa, perfectionism, and dopamine D4 receptor (DRD4)

1 reference

12 December 2020

10.1007/S11920-012-0287-6

Identifiers

DOI

1 reference

PubMed ID

22628000

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22628000